7 February 2019

In the American Journal of Respiratory and Critical Care Medicine Lindsey te Brake and colleagues described the shortcomings of a moderate increase in rifampicin dosing, the cornerstone TB drug.

Combined with ongoing trials to optimize the dose of rifampicin ≥35 mg/kg, powerful statistical pooled data analyses will help influence future treatment guidelines and improve the lives of millions of patients with tuberculosis worldwide.

Publication
Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.
Te Brake LHM, Boeree MJ, Aarnoutse RE.

Lindsey te Brake, Martin Boeree and Rob Aarnoutse are members of theme Infectious diseases and global health.

Related news items


Antibodies are sustained in nasal fluid after mild corona infection

27 September 2021 Testing through nasal fluids is easier than through blood read more

Less inflammation with a traditional Tanzanian diet than with a Western diet

18 February 2021 Study shows differences between western and traditional diet. read more

Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection

17 February 2021 In a review in Cell Mihai Netea, Frank van de Veerdonk, Reinout van Crevel and Jorge Dominguez Andres propose that induction of trained immunity by whole-microorganism vaccines may represent an important tool for reducing susceptibility to and severity of SARS-CoV-2. read more

ZonMw grants to study optimal use of COVID-19 vaccines in patients with impaired immune systems

3 February 2021 How do people with reduced immunity, especially kidney patients, react to a COVID-19 vaccination? And how can patients with peripheral arterial disease be helped by DNA testing? Our researchers received grants from ZonMw to make these studies possible. read more

New malaria mosquito is emerging in African cities

27 January 2021 A new urban mosquito is widespread in the Horn of Africa and is highly susceptible to local malaria parasites: a publication in Emerging Infectious Diseases. read more